Moorcraft SY, Fontana E, Cunningham D, et al. Characterising timing and pattern of relapse following surgery for localized esophagogastric adenocarcinoma: a retrospective study. BMC Cancer. 2016;16:112.
Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014;45:325–33.
Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomized, controlled trial. Lancet. 2010;376:687–97.
Kinoshita T, Kinoshita T, Saiura A, et al. Multicenter analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2015;102:102–7.
The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA. 1994;271:1587–92.
Wille-Jørgensen P, Syk I, Smedh K, et al. Effect of more vs less frequent follow-up testing on overall and colorectal cancer–specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA. 2018;319:2095–103. https://doi.org/10.1001/jama.2018.5623.
Cardoso R, Coburn NG, Seevaratnam R, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15(Suppl 1):S164–7. https://doi.org/10.1007/s10120-012-0142-9.
National Comprehensive Cancer Network. Retrieved 15 January 2017 at https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.<PUB1>
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. ESMO guidelines committee. Ann Oncol. 2016;27(Suppl 5):v38–49.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th ed). Gastric Cancer. 2020; https://doi.org/10.1007/s10120-020-01042-y. doi:https://doi.org/10.1007/s10120-020-01042-y. Published online ahead of print 14 February 2020.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer. N Engl J Med. 2006;355:11–20.
Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th edn. Hoboken: Wiley; 2017.
Lauren P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma, an attempt at a histo-clinicalclassification. Acta ParholMicrob Scan. 1965;64:31–49.
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.
Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of the literature by the Japanese Gastric Cancer Association Task Force. Gastric Cancer. 2014;17:26–33. https://doi.org/10.1007/s10120-013-0259-5.
Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015;26:644–56. https://doi.org/10.1093/annonc/mdu543.
Jiang DM, Suzuki C, Espin-Garcia O, et al. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. Cancer Med. 2020;9:3023–32. https://doi.org/10.1002/cam4.2948.
Zhang N, Liu HX, Kang DM, Wang N. [Lead time bias and its control in observational studies for clinical outcomes]. Zhonghua Liu Xing Bing XueZaZhi. 2018;39:700–3. https://doi.org/10.3760/cma.j.issn.0254-6450.2018.05.032 (PMID: 29860822 (in Chinese)).
Tan IT, So BY. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol. 2007;96:503–6. https://doi.org/10.1002/jso.20823.
Kodera Y, Ito S, Yamamura Y, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902. https://doi.org/10.1245/aso.2003.12.009.
Fujiya K, Tokunaga M, Makuuchi R, et al. Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer. Gastric Cancer. 2017;20(Suppl 1):141–9. https://doi.org/10.1007/s10120-016-0661-x.
Zanotti D, Baiocchi GL, Coniglio A, Mohammadi B, Ministrini S, Mughal M, et al. Follow-up after surgery for gastric cancer: how to do it. Updates Surg. 2018;70:293–9. https://doi.org/10.1007/s13304-018-0524-6 (PMID: 29582358).
Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21:315–23. https://doi.org/10.1007/s10120-017-0738-1.
Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3:1237–44. https://doi.org/10.1001/jamaoncol.2017.0515.
Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017;17:893. https://doi.org/10.1186/s12885-017-3918-9.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5 (PMID: 28993052).
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. (ToGA trial investigators). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. https://doi.org/10.1016/S0140-6736(10)61121-X (Epub 19 August 2010. Erratum in Lancet. 2010;376:1302. PMID: 20728210).
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2 (Epub 5 June 2021 PMID: 34102137).